A detailed history of Gw&K Investment Management, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Gw&K Investment Management, LLC holds 510,089 shares of NBIX stock, worth $64 Million. This represents 0.5% of its overall portfolio holdings.

Number of Shares
510,089
Previous 546,068 6.59%
Holding current value
$64 Million
Previous $75.2 Million 21.82%
% of portfolio
0.5%
Previous 0.69%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$114.58 - $153.15 $4.12 Million - $5.51 Million
-35,979 Reduced 6.59%
510,089 $58.8 Million
Q2 2024

Aug 12, 2024

BUY
$130.86 - $143.19 $2.38 Million - $2.61 Million
18,194 Added 3.45%
546,068 $75.2 Million
Q1 2024

May 08, 2024

SELL
$130.4 - $143.74 $1.05 Million - $1.16 Million
-8,088 Reduced 1.51%
527,874 $72.8 Million
Q4 2023

Feb 09, 2024

SELL
$106.07 - $132.76 $2 Million - $2.5 Million
-18,829 Reduced 3.39%
535,962 $70.6 Million
Q3 2023

Nov 09, 2023

SELL
$94.02 - $117.1 $1.8 Million - $2.24 Million
-19,164 Reduced 3.34%
554,791 $62.4 Million
Q2 2023

Aug 09, 2023

SELL
$89.53 - $104.87 $612,564 - $717,520
-6,842 Reduced 1.18%
573,955 $54.1 Million
Q1 2023

May 09, 2023

BUY
$94.11 - $123.02 $588,658 - $769,490
6,255 Added 1.09%
580,797 $58.8 Million
Q4 2022

Feb 10, 2023

SELL
$106.72 - $127.06 $2.22 Million - $2.64 Million
-20,786 Reduced 3.49%
574,542 $68.6 Million
Q3 2022

Nov 09, 2022

SELL
$92.03 - $107.81 $1.99 Million - $2.33 Million
-21,581 Reduced 3.5%
595,328 $63.2 Million
Q2 2022

Aug 09, 2022

SELL
$75.79 - $100.07 $4.74 Million - $6.26 Million
-62,530 Reduced 9.2%
616,909 $60.1 Million
Q1 2022

May 09, 2022

BUY
$72.45 - $94.81 $16 Million - $20.9 Million
220,824 Added 48.15%
679,439 $63.7 Million
Q4 2021

Feb 11, 2022

BUY
$79.65 - $106.22 $1.17 Million - $1.56 Million
14,733 Added 3.32%
458,615 $39.1 Million
Q3 2021

Nov 10, 2021

SELL
$86.18 - $99.03 $471,921 - $542,288
-5,476 Reduced 1.22%
443,882 $42.6 Million
Q2 2021

Aug 10, 2021

BUY
$89.43 - $102.27 $749,065 - $856,613
8,376 Added 1.9%
449,358 $43.7 Million
Q1 2021

May 11, 2021

BUY
$87.57 - $119.4 $4.7 Million - $6.41 Million
53,699 Added 13.87%
440,982 $42.9 Million
Q4 2020

Feb 05, 2021

SELL
$86.91 - $108.33 $158,176 - $197,160
-1,820 Reduced 0.47%
387,283 $37.1 Million
Q3 2020

Nov 10, 2020

BUY
$96.16 - $135.15 $1.17 Million - $1.64 Million
12,137 Added 3.22%
389,103 $37.4 Million
Q2 2020

Aug 06, 2020

BUY
$85.09 - $130.36 $279,265 - $427,841
3,282 Added 0.88%
376,966 $46 Million
Q1 2020

May 11, 2020

BUY
$75.11 - $113.76 $6.34 Million - $9.6 Million
84,421 Added 29.18%
373,684 $32.3 Million
Q4 2019

Feb 10, 2020

SELL
$86.8 - $118.57 $691,362 - $944,410
-7,965 Reduced 2.68%
289,263 $31.1 Million
Q3 2019

Nov 05, 2019

BUY
$83.82 - $101.5 $5.17 Million - $6.26 Million
61,645 Added 26.17%
297,228 $26.8 Million
Q2 2019

Aug 06, 2019

SELL
$72.24 - $91.27 $231,167 - $292,064
-3,200 Reduced 1.34%
235,583 $19.9 Million
Q1 2019

May 14, 2019

BUY
$69.31 - $91.53 $427,088 - $564,007
6,162 Added 2.65%
238,783 $21 Million
Q4 2018

Feb 07, 2019

BUY
$68.32 - $124.36 $15.9 Million - $28.9 Million
232,621 New
232,621 $16.6 Million
Q3 2018

Nov 06, 2018

SELL
$98.88 - $125.85 $8.12 Million - $10.3 Million
-82,146 Closed
0 $0
Q2 2018

Aug 07, 2018

SELL
$75.3 - $105.99 $26,355 - $37,096
-350 Reduced 0.42%
82,146 $8.07 Million
Q1 2018

May 08, 2018

SELL
$75.88 - $92.43 $685,424 - $834,920
-9,033 Reduced 9.87%
82,496 $6.84 Million
Q4 2017

Jan 19, 2018

BUY
$58.53 - $77.59 $572,716 - $759,218
9,785 Added 11.97%
91,529 $7.1 Million
Q3 2017

Oct 11, 2017

BUY
$47.97 - $61.28 $3.92 Million - $5.01 Million
81,744
81,744 $5.01 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Gw&K Investment Management, LLC Portfolio

Follow Gw&K Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gw&K Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gw&K Investment Management, LLC with notifications on news.